For decades, the imaging infrastructure behind respiratory clinical trials has relied on slow, manual processes that haven't kept pace with the science. Qureight is building the solution, and today we're announcing our lead investment in their $20m Series B.
Introducing Qureight
Qureight is a Cambridge-based, end-to-end imaging company on a mission to accelerate clinical trials. Its AI-powered platform provides enterprise-grade imaging and precision endpoints for the biopharmaceutical industry, helping customers bring treatments to market faster. The platform manages the full imaging workflow across global trial sites, from data ingestion and anonymisation through to central reads and regulatory-grade analytics, across therapeutic areas including idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, bronchiectasis and pulmonary hypertension.
Qureight's products include: global imaging CRO services to improve image handling and support rapid site onboarding and patient inclusion decisions; proprietary AI lung image biomarkers that quantify disease progression in clinical trials; and data science products including synthetic control arms, which enable comparisons to real trial arms to reduce study costs and duration.
The company’s biopharma customers have been asking for real-time insights and precision endpoints across a number of fibrotic lung diseases.
“We are strategically positioning ourselves to address this market with our end-to-end, integrated imaging platform for clinical trials. We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors.
Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new therapeutic areas, and solidify our leadership position in the lung and heart imaging CRO market.”
Why we're excited to invest
Qureight sits at an intersection combining the analytical depth of an AI platform with the operational rigour required for clinical contract research. The company’s platform, imaging biomarkers and workflows are purpose-built for the regulatory demands of drug development. Queright is already becoming the leading imaging platform for respiratory clinical trials.
What draws us to Qureight is the combination of a strong scientific foundation and a clear commercial opportunity. By every measure, lung and heart diseases represent one of the largest addressable markets in clinical development. Qureight's platform is already being used by biopharma partners in active trials, and the new AI imaging laboratory will allow the company to move rapidly into new therapeutic areas, including asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity, building on its existing strength in lung fibrosis.
The team, led by Dr Muhunthan Thillai, combines world-class clinical expertise with the engineering and commercial capability to scale. Dr. Inga Deakin will join Qureight's board as part of this investment.
"Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team's rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation. We look forward to working with Muhunthan and the team as they deliver on this vision.”
What Qureight plans to do with the funding
The $20m Series B was led by Molten Ventures, with existing investors Hargreave Hale AIM VCT, XTX Ventures, Guiness Ventures, Meltwind, and Ascension also participating.
The company is building a dedicated AI imaging laboratory to house Qureight's 3D chest imaging foundation model. This will significantly reduce both the data requirement and the time needed to develop new disease models, allowing the company to bring new products to market in areas where there is high demand for advanced imaging analytics: asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity. These new disease models will complement Qureight's existing work in lung fibrosis and expand the company's reach across the clinical trials market.
Learn more about Qureight at www.qureight.com
